The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris
Dr. Robin Carhart-Harris discusses how psychedelics like psilocybin and LSD change the brain, treating depression, anorexia, and trauma. He explains safe journey components, the role of experience, and the future legal landscape of these therapies.
Deep Dive Analysis
19 Topic Outline
Defining Psychedelics: Etymology and Pharmacology
Psychedelics and Revealing the Unconscious Mind
Microdosing vs. Macrodosing Psychedelics
The Role of Expectancy and Placebo in Microdosing
Psilocybin Dosing and Mushroom Conversion
Components of Psychedelic Therapy: Setting and Music
The Importance of 'Trust, Let Go, Be Open' in Psychedelic Journeys
Phases of Psychedelic Experience: Initial Anxiety to Breakthrough
Brain Connectivity Changes During and After Psychedelic Use
Neuroplasticity and Long-Term Effects of Psilocybin
Psilocybin Therapy for Anorexia Nervosa
The Integration Phase of Psychedelic Therapy
First-Time Psychedelic Use Study: Brain Changes and Cognition
Psilocybin Therapy for Fibromyalgia Syndrome
MDMA Therapy: Empathy, Inner Healer, and Trauma
Placebo Response in Psychedelic vs. Antidepressant Trials
LSD in Therapy: Duration and Practical Constraints
DMT: The 'Rocket Ship' Experience and Ego Dissolution
Legal Landscape and Future of Psychedelic Medicine
8 Key Concepts
Psychedelic
A term coined by Humphrey Osmond from ancient Greek 'psyche' (mind/soul) and 'delos' (to make clear/reveal). It refers to compounds that reveal aspects of the human mind or soul not ordinarily visible, encompassing both potentially hellish and heavenly experiences. Pharmacologically, classic psychedelics primarily act on the serotonin 2A receptor.
Unconscious Mind
In depth psychology, this refers to aspects of human nature and individual experiences (like repressed traumatic memories or difficult relationships) that are not fully available to conscious awareness. Psychedelics are believed to reveal this material, catalyzing therapeutic processes through emotional release and insight.
Microdosing
Taking a dose of a classic psychedelic, typically LSD or psilocybin, that produces sub-perceptible psychedelic effects, meaning it does not induce a noticeable altered state of consciousness or 'tripping.' The assumption is that it can improve well-being or cognition on a trait level without a full psychedelic experience, though compelling evidence is currently lacking.
Global Functional Connectivity
A measure of communication across different brain systems. Under psychedelic influence, the brain exhibits increased global functional connectivity, meaning communication transcends typical modular boundaries and becomes more 'inter-modular.' This effect correlates with the magnitude of subjective experience and, in some studies, with therapeutic outcomes for depression.
Entropic Brain Effect
An increase in the informational complexity of ongoing brain activity, often recorded with EEG, observed under the influence of psilocybin. The brain activity becomes harder to predict across time and more informationally rich, correlating reliably with the magnitude of the subjective psychedelic experience.
Neuroplasticity
The brain's ability to change and adapt. Psilocybin has been shown to induce neuroplastic changes, including potential increases in tract integrity (a decrease in axial diffusivity) in major white matter tracts connecting the prefrontal cortex, thalamus, and striatum. These changes are observed after a single session and are in a direction associated with healthy brain development.
Ego Dissolution
A temporary experience during a psychedelic trip characterized by a loss of the sense of self and personal boundaries, often leading to feelings of interconnectedness with others and the world. It's hypothesized to occur because classic psychedelics target serotonin 2A receptors heavily expressed in evolutionarily 'recent brain' (cortex), scrambling activity and spreading out the system.
Integration Phase
The period following a psychedelic dosing session where individuals process and incorporate the insights and experiences from their trip into their daily life. This 'work' is considered ongoing, potentially lasting a lifetime, and can be complemented by practices like meditation or spiritual practice to maintain positive changes.
10 Questions Answered
The word 'psychedelic' was coined by Humphrey Osmond in 1956, combining the ancient Greek words 'psyche' (mind or soul) and 'delos' (to make clear or reveal). It signifies that these compounds reveal ordinarily invisible aspects of the human mind or soul.
Classic psychedelics primarily work by acting as agonists (activators) on the serotonin 2A receptor in the brain. This activation leads to increased global functional connectivity, meaning more communication across different brain systems that typically operate modularly.
Broadly speaking, one gram of magic mushrooms is estimated to contain about 10 milligrams of psilocybin, assuming a psilocybin content of roughly 1% of the mushroom's mass.
Data from independent studies consistently show that the magnitude and quality of certain subjective experiences during a psychedelic session strongly and reliably predict therapeutic outcomes, suggesting the experience itself is a crucial component, not just an epiphenomenon.
During the early phase of a high-dose psychedelic trip, common fears include losing one's mind, going insane, or dying. This struggle is often against the general drug effects that break down the normal sense of assuredness about reality and self.
Yes, studies have shown that the increase in global functional connectivity (or decrease in modularity) can persist after the acute drug effects, observed the next day and even three weeks later in some depression cohorts. This change also correlates with improvements in symptom severity.
The integration phase is the period after a psychedelic session where individuals process and apply the insights gained to their daily lives. It's crucial because while the drug provides a 'foot up' or makes difficult work easier, the ongoing effort to integrate these changes is necessary for sustained therapeutic benefit, often compared to ongoing practices like meditation.
In a trial comparing psilocybin therapy to escitalopram (Lexapro), pre-trial expectancy for escitalopram strongly predicted its therapeutic response. However, even with high pre-trial expectancy for psilocybin, it did not predict the response to psilocybin therapy, suggesting a direct therapeutic action beyond a placebo effect.
LSD is less commonly used in trials primarily due to its significantly longer duration of effects (8+ hours), which makes study days impractically long and expensive for both participants and staff, especially when regulatory guidelines require extended post-dose monitoring.
MDMA therapy for PTSD is in Phase 3 trials, with data being filed with the FDA, and a decision is anticipated as early as this year, potentially leading to rollout by next year. Psilocybin therapy for treatment-resistant depression is also in Phase 3 trials, but these have just started, with the earliest estimate for regulatory approval around 2026.
20 Actionable Insights
1. Avoid Street Psychedelics
Exercise serious caution when considering purchasing MDMA or psychedelics from street sources, as they are increasingly being laced with dangerous contaminants like fentanyl, posing significant health risks.
2. Morning & Exercise Hydration
Dissolve one packet of Element in 16-32 ounces of water and drink it first thing in the morning and during any physical exercise to ensure adequate hydration and electrolyte intake for optimal brain and body function.
3. Daily Meditation & NSDR
Practice meditation, Yoga Nidra, or Non-Sleep Deep Rest (NSDR) regularly, even for short 10-minute sessions, to explore different states of consciousness and restore cognitive and physical energy.
4. Adopt “Trust, Let Go, Be Open”
During psychedelic therapy, cultivate a mindset of “trust, let go, be open” by building therapeutic rapport, surrendering to the experience without resistance, and being willing to confront difficult emotions and insights.
5. Sustain Psychedelic Integration
After psychedelic therapy, engage in ongoing integration work, viewing it as a continuous practice similar to meditation, to sustain the therapeutic gains and prevent relapse.
6. Confront Trauma Directly
To effectively deal with trauma, one must confront it directly to the point where some relief is experienced, as there is no other real way to achieve resolution.
7. Psychedelic Session Setup
During psychedelic therapy, wear an eye mask to keep eyes shut and listen to music that evolves from spacious to atmospheric, intentionally designed to coax emotion, as this is a staple component of the therapeutic process.
8. Choose Psychedelic for Trauma
For trauma, consider MDMA therapy to revisit difficult experiences with greater safety and trust, or classic psychedelics for a deeper, potentially more challenging but comprehensive exploration of the psyche, including both difficult and profound aspects.
9. Question Microdosing Efficacy
Be cautious about the perceived benefits of microdosing, as current scientific evidence suggests it does not compellingly beat placebo, with much of the reported effect attributed to positive expectancy.
10. Psychedelic Efficacy Beyond Placebo
Understand that the efficacy of classic psychedelic therapy is not primarily driven by positive pre-trial expectancy, suggesting that its therapeutic benefits are due to direct drug action and experience rather than a “super placebo” response.
11. Anticipate Core Psychedelic Fears
Be prepared for common core fears during the initial phase of a psychedelic experience, such as losing one’s mind or dying, as these are palpable and reliable aspects of the basic drug action.
12. Sustained Brain Connectivity Post-Trip
Understand that the increased brain connectivity observed during psychedelic experiences can persist for at least three weeks afterward, which is hypothesized to contribute to long-term positive therapeutic outcomes.
13. Utilize Music in Psychedelic Therapy
Recognize music as a staple and potentially synergistic component of psychedelic therapy, as all published studies showing positive outcomes incorporate music, suggesting its critical role in the combination treatment.
14. Address Relapse in Chronic Depression
For individuals with chronic depression, be aware that psychedelic therapy may offer a window of wellness, but relapse is common, suggesting the need for ongoing or repeated treatments.
15. Understand Psychedelic Session Durations
Be aware of the typical duration of psychedelic experiences: Psilocybin and MDMA sessions last approximately 4-6 hours, while LSD sessions can extend to 8 hours or more, which is crucial for planning and post-dose monitoring.
16. Psilocybin Mushroom Conversion (Caution)
Understand that one gram of magic mushrooms broadly contains about 10 milligrams of psilocybin, but this is guesswork and should not be used to calibrate self-dosing due to variability and potential for error.
17. LSD Perceptible Threshold
Recognize that the threshold for perceptible psychedelic effects with LSD is around 10-12 micrograms, which helps differentiate between sub-perceptible microdoses and doses that may induce altered states, though individual sensitivity varies.
18. Psilocybin for Anorexia Nervosa
Consider psilocybin therapy as a potential treatment for anorexia nervosa, as preliminary results indicate alleviation of obsessive thoughts about food, increased willingness to consume healthy amounts, and improved weight.
19. Psilocybin for Fibromyalgia
Consider psilocybin therapy as a potential treatment for fibromyalgia syndrome, as preliminary observations from a study using a single 25mg dose of psilocybin are showing profound experiences and very promising results for generalized chronic pain.
20. Typical Psychedelic Session Frequency
Understand that psychedelic therapy typically involves 1-3 dosing sessions, spaced 1-3 weeks apart, which provides a general framework for the number and frequency of sessions used in clinical trials.
5 Key Quotes
To fathom hell or so angelic, just take a pinch of psychedelic.
Humphrey Osmond (quoted by Robin Carhart-Harris)
Science is not about what you want to believe, it's about what's actually coming through and what seems to hold up to testing.
Robin Carhart-Harris
Psychedelic therapy allows you to sit with rather than sit on.
Former colleague of Robin Carhart-Harris
After the ecstasy, the laundry.
Jack Kornfield (quoted by Robin Carhart-Harris)
The ego might go away during the trip and you have these profound insights about the molecular continuity and how we're all one and interconnected and then you come down and however long later you know the ego comes back but maybe with a vengeance.
Robin Carhart-Harris
2 Protocols
General Psychedelic Therapy Session Setup
Robin Carhart-Harris- Patient is in settled conditions, typically with an eye mask to encourage 'going inside'.
- Music is played throughout the session, starting spacious and building atmospherically to coax emotion.
- Two mental health professionals (at least one psychiatrist, clinical psychologist, psychotherapist, or psychiatric nurse) are present with the individual who has ingested the drug.
Guidance Mantra for Psychedelic Journey
Bill Richards (attributed by Robin Carhart-Harris)- Trust: Build therapeutic rapport with the guides, which predicts the quality of the experience and therapeutic outcomes.
- Let Go: Cultivate a readiness to surrender and not resist the drug's effects.
- Be Open: Maintain a willingness to confront difficult emotions or memories and be inquisitive about the experience.